NS Biopharma Consulting

NS Biopharma Consulting was a private biotechnology consulting firm rather than a drug developer. Publicly accessible evidence indicates it was led by Christopher Rovaldi, who was identified in SEC disclosure as President of NS Biopharma Consulting, LLC beginning in May 2019. The firm appears to have provided consulting services to biotechnology companies, likely focused on biotech operations, development, and related strategic support rather than maintaining an internal therapeutic pipeline. There is no clear evidence that the company operated proprietary drug programs, platform technologies, or commercialized products. Available signals suggest it was a small, specialized consulting entity and may no longer be active as an operating business.